View clinical trials related to Melanoma Stage Iv.
Filter by:To evaluate if surgical removal of residual disease adds benefit in stage IV melanoma patients with partial response or stable disease after a minimum 9 months of first-line PD-1 inhibition. Primary endpoint: Disease-free survival (DFS) at 12 months.
This research study is studying different immunotherapy regimens as a possible treatment for stage III or IV resectable melanoma.